Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference

2025-09-15
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Jefferies Healthcare Services Conference in Nashville on Monday, September 29, 2025, at 4:35 p.m. Eastern Time.

US Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic

2025-09-15
The United States Drug Abuse Testing Market is projected to grow significantly, reaching US$ 3.71 billion by 2033, up from US$ 2 billion in 2024, reflecting a CAGR of 7.11% from 2025 to 2033. This growth is driven by increasing substance misuse, stringent workplace regulations, technological advancements, government support, and rising public awareness. The sector is essential in tackling drug-related challenges through innovative testing methods such as urine, saliva, hair, and blood analyses,

Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains

2025-09-11
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

2025-09-10
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript

2025-09-10
Get the latest insights from Quest Diagnostics at the 2025

Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

2025-09-10
MADISON, Wis., September 10, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when trea

Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine

2025-09-08
Quest Diagnostics (DGX) recently caught the market’s eye with the launch of an advanced pharmacogenomic laboratory test. The new test aims to help healthcare providers personalize drug therapies based on a patient’s genetic profile. Supported by Coriell Life Sciences technology, this service is positioned as a game changer for clinicians across a wide range of specialties. It offers actionable guidance that could make prescribing both safer and more effective. This launch also signals a...

3 Reasons to Sell DGX and 1 Stock to Buy Instead

2025-09-08
Even though Quest (currently trading at $183.49 per share) has gained 6% over the last six months, it has lagged the S&P 500’s 15.5% return during that period. This might have investors contemplating their next move.

Quest Diagnostics Inc. stock outperforms competitors on strong trading day

2025-09-05
Quest Diagnostics Inc. stock outperforms competitors on strong trading day

Quest Diagnostics introduces new pharmacogenomic testing service

2025-09-05
The PGx service comprises 17 genes and four HLA alleles, targeting genes with known drug associations and medical relevance.